A clinical trial of the dasatinib and quercetin cocktail demonstrated a decrease in p21 and p16 positive human adipose tissue cells and plasma SASP factors of diabetic kidney disease participants (Hickson et al., 2019). Here, CDKN1A is linked to diabetic kidney disease.